Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

Standard-of-care first-line treatment for metastatic urothelial carcinoma (mUC) is platinum-based chemotherapy (CTx). Maintenance immunotherapy is a treatment option for patients without progressive disease (PD) after induction CTx. IMvigor130 was a randomised, phase 3 study evaluating atezolizumab...

Full description

Bibliographic Details
Main Authors: Enrique Grande, Aristotelis Bamias, Matthew D. Galsky, Eiji Kikuchi, Ian D. Davis, José Ángel Arranz, Arash Rezazadeh Kalebasty, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Javier Puente, Jian-Ri Li, Sandrine Bernhard, Alan Nicholas, Julie Telliez, Maria De Santis
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:European Urology Open Science
Subjects:
Atezolizumab
Cancer immunotherapy
First line
IMvigor130
Induction chemotherapy
Maintenance treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168323012946

Similar Items

Similar Items